HRT Financial LLC bought a new position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,516 shares of the exchange traded fund’s stock, valued at approximately $258,000. HRT Financial LLC owned approximately 0.08% of ProShares Ultra Nasdaq Biotechnology as of its most recent SEC filing.
Separately, Virtu Financial LLC boosted its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 188.1% during the 2nd quarter. Virtu Financial LLC now owns 20,311 shares of the exchange traded fund’s stock worth $1,162,000 after buying an additional 13,262 shares during the period.
NASDAQ BIB opened at $65.22 on Friday. ProShares Ultra Nasdaq Biotechnology has a 1 year low of $48.12 and a 1 year high of $70.53.
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Further Reading: Index Funds
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.